Related Experiment Video
Updated: Aug 9, 2026

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis
Xiaohui Zhang1, Pengfei Li, Junying Bao
1Department of Pathology, University of South Florida College of Medicine, Tampa, Florida 33612, USA.
Abstract:
Recent studies suggest that growth inhibition by 1,25-dihydroxyvitamin D3 represents an innovative approach to ovarian cancer therapy. To understand the molecular mechanism of 1,25-dihydroxyvitamin D3 action, we profiled the hormone-induced changes in the transcriptome of ovarian cancer cells using microarray technology. More than 200 genes were identified to be regulated by 1,25-dihydroxyvitamin D3. Reverse transcription-PCR analyses confirmed the regulation of a group of apoptosis-related genes, including the up-regulation of the decoy receptor that inhibits tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) action, TRAIL receptor 4, and the down-regulation of Fas, the receptor that mediates the action of Fas ligand. The regulation was further confirmed at the protein level. Consistent with the regulation of the death receptors, pretreatment with 1,25-dihydroxyvitamin D3 decreased apoptosis induced by TRAIL and Fas ligand. Because persistent 1,25-dihydroxyvitamin D3 treatment has been shown to induce apoptosis in ovarian cancer, the hormone appears to exert a dual effect on the death of ovarian cancer cells. Knockdown of TRAIL receptor 4 by RNA interference or ectopic expression of Fas relieved the suppressive effect of 1,25-dihydroxyvitamin D3, showing that molecular manipulation of death receptors is a viable approach to overcome the protective effect of 1,25-dihydroxyvitamin D3 on the apoptosis of ovarian cancer. These strategies may allow ovarian cancer patients to benefit from therapy with both 1,25-dihydroxyvitamin D3 and ligands for death receptors, such as TRAIL, shown to selectively induce apoptosis in cancer but not normal cells.
Insights
1,25-dihydroxyvitamin D3 shows dual effects on ovarian cancer cell death, initially inhibiting apoptosis by altering death receptor expression. Manipulating these receptors can overcome this protective effect for combined therapies.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- 1,25-dihydroxyvitamin D3 (calcitriol) is explored for ovarian cancer therapy due to its growth-inhibiting properties.
- Understanding the molecular mechanisms of calcitriol's action is crucial for optimizing its therapeutic potential.
Purpose of the Study:
- To investigate the molecular mechanisms by which 1,25-dihydroxyvitamin D3 affects ovarian cancer cell apoptosis.
- To identify key genes and pathways regulated by calcitriol in ovarian cancer cells.
Main Methods:
- Microarray analysis to profile transcriptome-wide changes induced by 1,25-dihydroxyvitamin D3.
- Reverse transcription-PCR and Western blot to validate gene and protein expression changes.
- RNA interference and ectopic expression to assess the role of specific death receptors.
Main Results:
- Over 200 genes were identified as regulated by 1,25-dihydroxyvitamin D3 in ovarian cancer cells.
- Calcitriol up-regulated TRAIL receptor 4 (decoy receptor) and down-regulated Fas (death receptor) at transcript and protein levels.
- Pretreatment with calcitriol reduced apoptosis induced by TRAIL and Fas ligand, indicating a protective effect.
Conclusions:
- 1,25-dihydroxyvitamin D3 exhibits a dual role in ovarian cancer cell death, potentially inhibiting apoptosis via modulation of death receptors.
- Targeting TRAIL receptor 4 and Fas can overcome the protective effects of calcitriol, suggesting combination therapy strategies.
- Molecular manipulation of death receptors may enable patients to benefit from combined treatments with calcitriol and death receptor ligands like TRAIL.
More Related Videos
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Apoptosis
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Cellular Injury V: Apoptosis and Autophagy